Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nancy Hindalong

Nurse Practitioner Lecanto, FL Nurse Practitioner

NPI 1164075560 CMS profile 11190436

525 N Dacie Pt, Lecanto, FL 34461

Open in the dashboard

General payments

$7,109

283 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nancy Hindalong of Lecanto, FL is reported in the CMS Open Payments database as having received $7,109 across 283 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,422 51
2024 General $1,925 67
2023 General $1,886 70
2022 General $1,244 66
2021 General $631 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nancy Hindalong
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Nancy Hindalong were reported at $1,422. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Nancy Hindalong Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $631 $135 $40–$426 $132
2022 $1,244 $152 $48–$470 $149
2023 $1,886 $166 $54–$529 $160
2024 $1,925 $173 $55–$556 $164
2025 $1,422 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $1,159 30 payments
  2. UCB, Inc. $981 34 payments
  3. AbbVie, Inc. $782 44 payments
  4. Regeneron Healthcare Solutions, Inc. $634 27 payments
  5. Sun Pharmaceutical Industries Inc. $604 18 payments
  6. E.R. Squibb & Sons, L.L.C. $559 24 payments
  7. Genzyme Corporation $415 16 payments
  8. Lilly USA, LLC $386 16 payments
  9. Novartis Pharmaceuticals Corporation $357 16 payments
  10. LEO Pharma Inc. $246 12 payments
  11. Other $984 46 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,742 277 payments
  2. Education $367 6 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $1,175 27 payments
  2. Cimzia $575 23 payments
  3. SOTYKTU $543 23 payments
  4. DUPIXENT Immunology $466 18 payments
  5. ILUMYA $438 14 payments
  6. Bimzelx $407 11 payments
  7. TALTZ $339 14 payments
  8. RINVOQ $335 17 payments
  9. DUPIXENT Inflammation And Immunology $330 20 payments
  10. SKYRIZI $311 18 payments
  11. Other $3,256 146 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,646

Median for Nurse Practitioner: 389

Drug cost

$164,407

Median for Nurse Practitioner: $21,885

Branded share of claims

13.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 33 $126,680
Clobetasol Propionate Generic 159 $11,394
Ciclopirox Ciclopirox Olamine Brand 148 $4,021
Fluocinonide Generic 106 $3,907
Metronidazole Generic 64 $3,520
Triamcinolone Acetonide Generic 358 $3,118
Doxycycline Hyclate Generic 147 $1,881
Fluorouracil Generic 26 $1,631
Tretinoin Generic 16 $1,442
Ciclopirox Generic 32 $897

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$324,446

Of which drugs: $32,751

Medicare patients

1,631

Average age 77

Services billed

9,096

956 women, 675 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Chronic kidney disease 36%
Ischemic heart disease 32%
Diabetes 28%
Depression 24%
COPD 23%
Atrial fibrillation 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 14 16 $12

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $448
$448 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $269
$269 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $149
  • GENZYME CORPORATION $88
$237 33 —
Bimzelx
  • UCB, Inc. $228
$228 — —
ILUMYA
  • Sun Pharmaceutical Industries Inc. $181
$181 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

283 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record